David Wang‐Iverson
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Analytical Chemistry and Chromatography, Chromatography in Natural Products, Microfluidic and Capillary Electrophoresis Applications, Lipoproteins and Cardiovascular Health, Mass Spectrometry Techniques and Applications
Most-Cited Works
- → The Thyroid Hormone Receptor-β-Selective Agonist GC-1 Differentially Affects Plasma Lipids and Cardiac Activity1(2000)274 cited
- → Enantioselective chromatography in drug discovery(2005)186 cited
- → Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin(1990)146 cited
- → In Vitro Myotoxicity of the 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors, Pravastatin, Lovastatin, and Simvastatin, Using Neonatal Rat Skeletal Myocytes(1995)132 cited
- → A tris (2-carboxyethyl) phosphine (TCEP) related cleavage on cysteine-containing proteins(2010)75 cited
- → Characterization of protein therapeutics by mass spectrometry: recent developments and future directions(2010)71 cited
- → Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies(2011)61 cited
- → Quantification of 4-Beta-Hydroxycholesterol in Human Plasma Using Automated Sample Preparation and LC-ESI-MS/MS Analysis(2011)46 cited
- → Pharmacokinetic interaction between propranolol and the HMG‐CoA reductase inhibitors pravastatin and lovastatin.(1991)43 cited
- → Determination of SQ 33,600, a phosphinic acid containing HMG CoA reductase inhibitor, in human serum by high-performance liquid chromatography combined with ionspray mass spectrometry(1992)26 cited